TransMedics Group, Inc. $TMDX Shares Bought by Yousif Capital Management LLC

Yousif Capital Management LLC raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,908 shares of the company’s stock after acquiring an additional 277 shares during the period. Yousif Capital Management LLC’s holdings in TransMedics Group were worth $1,730,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Smartleaf Asset Management LLC raised its holdings in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. CWM LLC lifted its holdings in shares of TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company’s stock valued at $62,000 after buying an additional 155 shares during the period. Maryland State Retirement & Pension System lifted its holdings in shares of TransMedics Group by 1.9% in the 2nd quarter. Maryland State Retirement & Pension System now owns 9,943 shares of the company’s stock valued at $1,332,000 after buying an additional 185 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of TransMedics Group in the second quarter worth about $26,000. Finally, KLP Kapitalforvaltning AS grew its holdings in TransMedics Group by 3.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,600 shares of the company’s stock worth $884,000 after acquiring an additional 200 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Up 1.7%

Shares of NASDAQ:TMDX opened at $117.63 on Monday. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $145.50. The company has a market capitalization of $4.01 billion, a price-to-earnings ratio of 60.95 and a beta of 2.08. The business has a 50-day moving average price of $116.52 and a 200 day moving average price of $113.94. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TMDX. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Monday, August 25th. Canaccord Genuity Group restated a “buy” rating and issued a $142.00 target price on shares of TransMedics Group in a report on Tuesday, October 14th. Finally, Evercore ISI began coverage on TransMedics Group in a report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $127.18.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.